InMed has a lead drug candidate in clinical development—INM-755, a CBN-based topical dermatological cream for the treatment of epidermolysis bullosa; a second drug candidate in preclinical ...
INmune Bio’s (INMB) treatment of epidermolysis bullosa received FDA orphan designation, according to a post on the agency’s site. Published first on TheFly – the ultimate source for real ...
as a potential new treatment for recessive dystrophic epidermolysis bullosa (RDEB). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of April 29, 2025. "The FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback